Home > Result Summaries: Compounds > naratriptan > Result Summary for S2WA4002

Result Summary for S2WA4002

Result Summary

Protocol ID:	S2WA4002
Clinical Study ID:	S2WA4002
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
Phase:	Phase 4
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non responders. Stark, S MD, O'Quinn, S MD, McNeal, S MD, Pait, G MD, and Watson, C MD American Academy of Neurology 51st Annual Meeting 4/17/1999 Toronto, Canada Stark S; Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan: HEADACHE 2000;40(7)513-520. Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non-responders. Spierings, E L H, Stark, S, O'Quinn, S, McNeal, S, Pait, G, and Watson, C 9th Congress of the International Headache Society 6/22/1999 Barcelona, Spain Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non responders. Stark, S MD, O'Quinn, S MD, McNeal, S MD, Putnam, G MD, and Watson, C MD 41st Annual Scientific Meeting of the American Association for the Study of Headache 6/11/1999 Boston, MA